Literature DB >> 19342893

Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway.

Emmett V Schmidt1, Michael J Ravitz, Li Chen, Mary Lynch.   

Abstract

Among other signals, cell growth is particularly controlled by the target of rapamycin (TOR) pathway that includes the tuberous sclerosis complex genes (TSC1/2), and through transcriptional effects regulated by c-myc. Overexpression of Drosophila Myc and TSC1/2 cause opposing growth and proliferation defects. Despite this relationship, direct regulatory connections between Myc and the TSC have only recently been evaluated. Other than studies of p53 regulation, little consideration has been given to transcriptional regulation of the TSC genes. Here we review evidence that transcriptional controls are potentially important regulators of TSC2 expression, and that Myc is a direct repressor of its expression. Since tuberin loss de-represses Myc protein, the connection between these two growth regulators is positioned to act as a feed-forward loop that would amplify the oncogenic effects of decreased tuberin or increased Myc. Further experiments will be needed to clarify the mechanisms underlying this important connection, and evaluate its overall contribution to cancers caused by TSC loss or Myc gain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19342893      PMCID: PMC2865178          DOI: 10.4161/cc.8.9.8215

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  109 in total

1.  Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination.

Authors:  M K Mateyak; A J Obaya; S Adachi; J M Sedivy
Journal:  Cell Growth Differ       Date:  1997-10

2.  Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway.

Authors:  M J West; M Stoneley; A E Willis
Journal:  Oncogene       Date:  1998-08-13       Impact factor: 9.867

3.  C-Myc 5' untranslated region contains an internal ribosome entry segment.

Authors:  M Stoneley; F E Paulin; J P Le Quesne; S A Chappell; A E Willis
Journal:  Oncogene       Date:  1998-01-22       Impact factor: 9.867

4.  Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site.

Authors:  C Nanbru; I Lafon; S Audigier; M C Gensac; S Vagner; G Huez; A C Prats
Journal:  J Biol Chem       Date:  1997-12-19       Impact factor: 5.157

5.  Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors.

Authors:  E P Henske; L L Wessner; J Golden; B W Scheithauer; A O Vortmeyer; Z Zhuang; A J Klein-Szanto; D J Kwiatkowski; R S Yeung
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

6.  Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis.

Authors:  R S Yeung; C D Katsetos; A Klein-Szanto
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

7.  Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.

Authors:  T A Smolarek; L L Wessner; F X McCormack; J C Mylet; A G Menon; E P Henske
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

8.  Loss of heterozygosity in the tuberous sclerosis gene associated regions in adenocarcinoma of the lung accompanied by multiple atypical adenomatous hyperplasia.

Authors:  K Suzuki; T Ogura; T Yokose; K Nagai; K Mukai; T Kodama; Y Nishiwaki; H Esumi
Journal:  Int J Cancer       Date:  1998-08-21       Impact factor: 7.396

9.  LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast.

Authors:  R A Lininger; W S Park; Y G Man; T Pham; G MacGrogan; Z Zhuang; F A Tavassoli
Journal:  Hum Pathol       Date:  1998-10       Impact factor: 3.466

10.  A large TSC2 and PKD1 gene deletion is associated with renal and extrarenal signs of autosomal dominant polycystic kidney disease.

Authors:  L Longa; F Scolari; A Brusco; C Carbonara; S Polidoro; B Valzorio; P Riegler; N Migone; R Maiorca
Journal:  Nephrol Dial Transplant       Date:  1997-09       Impact factor: 5.992

View more
  25 in total

1.  mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.

Authors:  Valerie L Sodi; Sakina Khaku; Raisa Krutilina; Luciana P Schwab; David J Vocadlo; Tiffany N Seagroves; Mauricio J Reginato
Journal:  Mol Cancer Res       Date:  2015-01-30       Impact factor: 5.852

2.  Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC.

Authors:  Lianpin Wu; Baozhu Yi; Shi Wei; Dapeng Rao; Youhua He; Gurudatta Naik; Sejong Bae; Xiaoguang M Liu; Wei-Hsiung Yang; Guru Sonpavde; Runhua Liu; Lizhong Wang
Journal:  Cancer Res       Date:  2019-02-07       Impact factor: 12.701

3.  Inhibition of mTORC1 signaling sensitizes hepatocellular carcinoma cells to glycolytic stress.

Authors:  Xin Zhao; Peng Jiang; Xiang Deng; Zhonghu Li; Feng Tian; Fei Guo; Xiaowu Li; Shuguang Wang
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

4.  A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.

Authors:  Pin Liu; Mengmeng Ge; Junjie Hu; Xiaolei Li; Li Che; Kun Sun; Lili Cheng; Yuedong Huang; Maria G Pilo; Antonio Cigliano; Giovanni M Pes; Rosa M Pascale; Stefania Brozzetti; Gianpaolo Vidili; Alberto Porcu; Antonio Cossu; Giuseppe Palmieri; Maria C Sini; Silvia Ribback; Frank Dombrowski; Junyan Tao; Diego F Calvisi; Ligong Chen; Xin Chen
Journal:  Hepatology       Date:  2017-05-22       Impact factor: 17.425

5.  Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.

Authors:  Luciana Schultz; Roula Albadine; Jessica Hicks; Sana Jadallah; Angelo M DeMarzo; Ying-Bei Chen; Matthew E Nielsen; Matthew E Neilsen; Mark L Gonzalgo; David Sidransky; Mark Schoenberg; George J Netto
Journal:  Cancer       Date:  2010-10-11       Impact factor: 6.860

6.  Regulation of gene expression in hepatic cells by the mammalian Target of Rapamycin (mTOR).

Authors:  Rosa H Jimenez; Ju-Seog Lee; Mirko Francesconi; Gastone Castellani; Nicola Neretti; Jennifer A Sanders; John Sedivy; Philip A Gruppuso
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

Review 7.  mTOR, metabolism, and the regulation of T-cell differentiation and function.

Authors:  Adam T Waickman; Jonathan D Powell
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

8.  Rapamycin and dexamethasone during pregnancy prevent tuberous sclerosis complex-associated cystic kidney disease.

Authors:  Morris Nechama; Yaniv Makayes; Elad Resnick; Karen Meir; Oded Volovelsky
Journal:  JCI Insight       Date:  2020-07-09

Review 9.  mTOR and lymphocyte metabolism.

Authors:  Hu Zeng; Hongbo Chi
Journal:  Curr Opin Immunol       Date:  2013-05-28       Impact factor: 7.486

10.  MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.

Authors:  Yifei Wang; Min Zhang; Zehua Wang; Weiwei Guo; Da Yang
Journal:  Mol Carcinog       Date:  2020-08-18       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.